Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chronic myeloid leukemia
(
CML
) originates from normal hematopoietic stem cells acquiring BCR-ABL fusion gene, specific BCR-ABL inhibitors (e.g., imatinib mesylate, IM) have greatly improved patient management. However, some patients are still suffering from relapse and drug resistance, which urges better understanding of the growth/survival mechanisms of
CML
stem/progenitor cells. In the present study, the role and its underlying mechanism of
heterogeneous nuclear ribonucleoprotein D-like
(
HNRPDL
) in
CML
cells were investigated. Firstly, overexpression of
HNRPDL
promoted the growth of murine BaF3 cells in vitro and induced leukemia in vivo, which was enhanced by co-expression of BCR-ABL. Conversely,
HNRPDL
silencing inhibited colony-forming cell (CFC) production of
CML
CD34
+
cells and attenuated BCR-ABL induced leukemia. In addition,
HNRPDL
modulated imatinib response of K562 cells and
HNRPDL
silencing sensitized
CML
CD34
+
cells to imatinib treatment. Mechanistically, we found the stability of pre-B-cell leukemia homeobox 1 (PBX1) mRNA was sustained by
HNRPDL
through its binding to a specific motif (ACUAGC) in 3'-untranslated region (3'-UTR) of PBX1. The expression of PBX1 was significantly higher in
CML
CD34
+
cells than that in control cells and PBX silencing inhibited the growth of
CML
cells and sensitized them to imatinib treatment. In contrast, overexpression of PBX1 elevated the CFC production of normal hematopoietic CD34
+
cells and "rescued"
HNRPDL
silencing induced growth inhibition and imatinib sensitization. Taken together, our data have demonstrated that
HNRPDL
transforms hematopoietic cells and a novel
HNRPDL
/PBX1 axis plays an important role in human
CML
CD34
+
cells.
...
PMID:Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34
+
cells via pre-B-cell leukemia homeobox 1. 3148 72